Welcome to our dedicated page for Vivani Medical news (Ticker: VANI), a resource for investors and traders seeking the latest updates and insights on Vivani Medical stock.
Vivani Medical, Inc. (Nasdaq: VANI) is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants based on its NanoPortal™ platform, along with neuromodulation devices through its Cortigent subsidiary. The VANI news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how Vivani’s clinical programs, financings, and corporate actions evolve over time.
Recent Vivani news has highlighted progress with NPM-139, a semaglutide GLP-1 implant program for chronic weight management, including plans for a Phase 1 clinical study and preparations for a potential Phase 2 dose-ranging trial, subject to regulatory clearance and supportive data. The company has also reported results from the LIBERATE-1 Phase 1 study of its exenatide implant NPM-115, which it describes as the first-in-human application of the NanoPortal technology, as well as preclinical data suggesting sustained weight loss from a single NPM-139 implant in ongoing studies.
In addition to R&D updates, Vivani’s news flow includes announcements of equity financings, such as private placements and a registered direct offering of common stock, with stated use of proceeds for research, clinical development, working capital and general corporate purposes. The company also issues news about its proposed spin-off of Cortigent, Inc., which develops brain implant devices like the Orion® visual cortical prosthesis system and a stroke recovery neurostimulation platform.
Investors and followers of VANI can use this page to monitor clinical milestones, capital-raising transactions, conference presentations, and key steps in the Cortigent spin-off process, all drawn from Vivani’s own press releases and related regulatory communications.
Vivani Medical (Nasdaq: VANI) has provided a business update and first quarter 2024 financial results. The company is advancing the development of GLP-1 implants for chronic weight management and type 2 diabetes. Key highlights include the initiation of preclinical activities for NPM-115 and the expected IND submission by year-end. A $15-million stock offering in March will fund operations until the second half of 2025. Vivani reported a cash balance of $31.0 million as of March 31, 2024, a net loss of $6.0 million, and a slight reduction in R&D and administrative expenses compared to the previous year.
Vivani Medical, Inc. (Nasdaq: VANI) will present at the TIDES Conference 2024 in Boston to discuss its lead asset NPM-115 for chronic weight management and NPM-119 for type 2 diabetes. The presentation will cover the Company's NanoPortal™ platform and updates on its programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Vivani Medical (VANI)?
What is the market cap of Vivani Medical (VANI)?
